Amicus (NASDAQ:FOLD) Therapeutics, Inc. (NASDAQ:FOLD) has seen a notable transaction from its President and CEO, Bradley L. Campbell, as he sold 7,500 shares of common stock at prices ranging from $11.53 to $11.76, with a weighted average price of $11.6661, according to the latest SEC filings. The total value of the shares sold by Campbell amounted to $87,495.
The transactions took place on April 1, 2024, and were part of a prearranged 10b5-1 trading plan, which allows company insiders to set up a predetermined plan to buy or sell company stock. This plan was adopted by Campbell on August 23, 2023, indicating that the trades were planned well in advance and not based on any immediate, undisclosed information that could affect the company's stock price.
In addition to the sales, Campbell also acquired 7,500 shares of Amicus Therapeutics through the exercise of stock options, with each option having a strike price of $8.61. The total value for these option exercises was $64,574. As noted in the SEC filing, all of the options were fully vested and exercisable as of the transaction date.
Following these transactions, Campbell's ownership in the company stands at 886,654 shares of common stock directly held. The sales and option exercises were conducted in accordance with SEC regulations, and full information regarding the number of shares sold at each separate price within the reported range is available upon request.
Investors often monitor insider transactions as they can provide insights into how top executives view the company's stock value and future prospects. Amicus Therapeutics, headquartered in Philadelphia, Pennsylvania, specializes in pharmaceutical preparations and continues to be a key player in the biotechnology industry.
InvestingPro Insights
Amicus Therapeutics, Inc. (NASDAQ:FOLD) has been in the spotlight following insider transactions by its President and CEO, Bradley L. Campbell. In light of these events, it's worth noting some key financial metrics and analyst insights from InvestingPro that could influence investor perception.
One standout feature of Amicus Therapeutics is its impressive gross profit margin, which was reported at a robust 90.65% for the last twelve months as of Q4 2023. This indicates the company's strong ability to manage its cost of goods sold and maintain profitability on its products. Additionally, the company's revenue growth for the same period was 21.3%, showcasing its expanding operations.
However, the company is currently not profitable, with a negative P/E ratio of -22.08, and an adjusted P/E ratio for the last twelve months as of Q4 2023 standing at -24.62. This reflects the challenges Amicus Therapeutics faces in achieving net profitability despite its high gross margins.
From an investment standpoint, Amicus Therapeutics is trading at a high Price / Book multiple of 20.97, which may suggest the stock is priced optimistically relative to the company's book value. This metric, combined with the fact that 2 analysts have revised their earnings downwards for the upcoming period, could be a concern for potential investors.
For those interested in further insights, there are additional InvestingPro Tips available that could shed more light on the company's financial health and future prospects. For instance, Amicus Therapeutics operates with a moderate level of debt and its liquid assets exceed short-term obligations, which suggests a stable financial position. Moreover, analysts predict the company will be profitable this year, which could be a turning point for the firm.
For a deeper dive into Amicus Therapeutics and to access more exclusive analysis, consider subscribing to InvestingPro. Use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With this subscription, you'll gain access to a wealth of financial data and insights, including the full list of InvestingPro Tips that can help you make more informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.